Spiradenoma Treatment & Management

  • Author: Noah S Scheinfeld, MD, JD, FAAD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Aug 2, 2011
 

Medical Care

Radiation, hyperthermic limb perfusion chemotherapy, and chemotherapy are used in the treatment of malignant spiradenomas. The mechanism for hyperthermic limb perfusion chemotherapy is uncertain, but some think that alterations of temperatures affect tumor cells more than healthy cells, which by analogy is like the increased sensitivity of cancer cells to radiation.

Although spiradenomas can be painful, they are not treated with medications. Sridhar et al[41] and Mirza et al[42] separately reported symptomatic improvement and shrinkage of malignant spiradenomas with tamoxifen therapy in a patient with estrogen receptor–positive eccrine adenocarcinoma.

Next

Surgical Care

The mainstay of treatment of spiradenomas and malignant spiradenomas is surgical removal. If tumors are painful, spiradenomas can be removed by surgical excision. The lesions do not tend to recur after surgery.

Multiple spiradenomas, such as those found in Brooke-Spiegler syndrome, were treated with a high-energy continuous wave carbon dioxide laser after debulking with bipolar scissors in one patient.[43] Debulking with bipolar scissors prior to laser therapy can be a beneficial technique in the surgical removal of large tumors.

Previous
Next

Consultations

If malignant spiradenomas are present, consult an oncologist, a radiation oncologist, and a radiologist.

Previous
Next

Activity

Sometimes, pain can bother patients, but this pain should not affect their activities.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Noah S Scheinfeld, MD, JD, FAAD  Assistant Clinical Professor, Department of Dermatology, Columbia University College of Physicians and Surgeons; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, and New York Eye and Ear Infirmary; Private Practice

Noah S Scheinfeld, MD, JD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Optigenex Consulting fee Independent contractor

Specialty Editor Board

Evan R Farmer, MD  Clinical Professor of Pathology and Dermatology, Department of Pathology, Virginia Commonwealth University School of Medicine

Evan R Farmer, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, American Medical Association, American Society of Dermatopathology, and International Society of Dermatology

Disclosure: Nothing to disclose.

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD  Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Consulting fee Consulting; Celgene Honoraria Safety Monitoring Committee; GSK - Glaxo Smith Kline Consulting fee Consulting; TenXBioPharma Consulting fee Safety Monitoring Committee

Joel M Gelfand, MD, MSCE  Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Kerstein DW, Helwig EB. Eccrine spiradenoma. AMA Arch Derm. Mar 1956;73(3):199-227. [Medline].

  2. Ekmekci TR, Koslu A, Sakiz D. Congenital blaschkoid eccrine spiradenoma on the face. Eur J Dermatol. Mar-Apr 2005;15(2):73-4. [Medline].

  3. Scheinfeld NS, Tarlow MM, Burgin S. Blaschkoid eccrine spiradenomas. Cutis. Jul 2002;70(1):73-5. [Medline].

  4. Dabska M. Malignant transformation of eccrine spiradenoma. Pol Med J. 1972;11(2):388-96. [Medline].

  5. Bumgardner AC, Hsu S, Nunez-Gussman JK, Schwartz MR. Trichoepitheliomas and eccrine spiradenomas with spiradenoma/cylindroma overlap. Int J Dermatol. May 2005;44(5):415-7. [Medline].

  6. Clarke J, Ioffreda M, Helm KF. Multiple familial trichoepitheliomas: a folliculosebaceous-apocrine genodermatosis. Am J Dermatopathol. Oct 2002;24(5):402-5. [Medline].

  7. Kazakov DV, Schaller J, Vanecek T, Kacerovska D, Michal M. Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors. J Cutan Pathol. Aug 2010;37(8):886-90. [Medline].

  8. Dijkhuizen T, van den Berg E, Nikkels PG, Hoekstra HJ, de Jong B. Cytogenetics of a case of eccrine spiradenoma. Hum Pathol. Sep 1992;23(9):1085-7. [Medline].

  9. Mambo NC. Eccrine spiradenoma: clinical and pathologic study of 49 tumors. J Cutan Pathol. Oct 1983;10(5):312-20. [Medline].

  10. Yildirim S, Akoz T, Akan M, Ege GA. De novo malignant eccrine spiradenoma with an interesting and unusual location. Dermatol Surg. Apr 2001;27(4):417-20. [Medline].

  11. Granter SR, Seeger K, Calonje E, Busam K, McKee PH. Malignant eccrine spiradenoma (spiradenocarcinoma): a clinicopathologic study of 12 cases. Am J Dermatopathol. Apr 2000;22(2):97-103. [Medline].

  12. Chou SC, Lin SL, Tseng HH. Malignant eccrine spiradenoma: a case report with pulmonary metastasis. Pathol Int. Mar 2004;54(3):208-12. [Medline].

  13. Kao GF, Laskin WB, Weiss SW. Eccrine spiradenoma occurring in infancy mimicking mesenchymal tumor. J Cutan Pathol. Aug 1990;17(4):214-9. [Medline].

  14. Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M. Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol. Feb 2005;27(1):27-33. [Medline].

  15. Amoroso C, Grandi E, Carinci F. Eccrine spiradenoma of the ear: case report. Int J Oral Maxillofac Surg. Dec 2003;32(6):662-3. [Medline].

  16. Nadig SK, Alderdice JM, Adair RA, Rao TJ. Eccrine spiradenoma: an unusual presentation with otalgia. Otolaryngol Head Neck Surg. Feb 2004;130(2):277-8. [Medline].

  17. Meyer TK, Rhee JS, Smith MM, Cruz MJ, Osipov VO, Wackym PA. External auditory canal eccrine spiradenocarcinoma: a case report and review of literature. Head Neck. Jun 2003;25(6):505-10. [Medline].

  18. Leach BC, Graham BS. Papular lesion of the proximal nail fold. Eccrine spiradenoma. Arch Dermatol. Aug 2004;140(8):1003-8. [Medline].

  19. Chen G, Cheuk W, Cheung JS, Chan JK. Carcinosarcoma ex eccrine spiradenoma of the vulva: report of the first case. Int J Gynecol Pathol. May 2011;30(3):301-5. [Medline].

  20. Amann J, Spraul CW, Mattfeld T, Lang GK. [Eccrine spiradenoma of the eyelid]. Klin Monbl Augenheilkd. Jan 1999;214(1):53-4. [Medline].

  21. Gupta S, Radotra BD, Kaur I, Handa S, Kumar B. Multiple linear eccrine spiradenomas with eyelid involvement. J Eur Acad Dermatol Venereol. Mar 2001;15(2):163-6. [Medline].

  22. Beekley AC, Brown TA, Porter C. Malignant eccrine spiradenoma: a previously unreported presentation and review of the literature. Am Surg. Mar 1999;65(3):236-40. [Medline].

  23. Jamshidi M, Nowak MA, Chiu YT, Perry EA, Fatteh SM. Giant malignant eccrine spiradenoma of the scalp. Dermatol Surg. Jan 1999;25(1):45-8. [Medline].

  24. Arslan E, Unal S, Cinel L, Demirkan F, Cin I. Malignant eccrine spiradenoma occurring on a traumatized area. Plast Reconstr Surg. Jul 2002;110(1):365-7. [Medline].

  25. Chase DM, Basu T, Saffari B, Ries S, Berman ML. Malignant eccrine spiradenoma of the vulva: a case report and review of the literature. Int J Gynecol Cancer. May-Jun 2006;16(3):1465-9. [Medline].

  26. Jariwala A, Evans A, McLeod G. Not all stubbed toes are innocuous--A case report of rare malignant eccrine spiradenoma (spiradenocarcinoma) of the toe. Foot Ankle Surg. Jun 2010;16(2):e32-3. [Medline].

  27. Siegel HJ, Said-Al-Naief N, Long J, Lopez-Ben RR, Klein M. Giant eccrine spiradenoma of the hand. Am J Orthop (Belle Mead NJ). Aug 2008;37(8):E141-3. [Medline].

  28. Turhan-Haktanir N, Demir Y, Tokyol C. A case of eccrine spiradenoma arising in nevus sebaceous in an adolescent girl. Am J Dermatopathol. Apr 2008;30(2):196-7. [Medline].

  29. Rodriguez-Martin M, Sanchez Gonzalez R, Saez-Rodríguez M, Garcia-Bustínduy M, Martín-Herrera A, Noda-Cabrera A. An unusual case of congenital linear eccrine spiradenoma. Pediatr Dermatol. Mar-Apr 2009;26(2):180-3. [Medline].

  30. Englander L, Emer JJ, McClain D, Amin B, Turner RB. A rare case of multiple segmental eccrine spiradenomas. J Clin Aesthet Dermatol. Apr 2011;4(4):38-44. [Medline]. [Full Text].

  31. Han YD, Huan Y, Deng JL, Zhang YG, Zhang CH. MRI appearance of multiple eccrine spiradenoma. Br J Radiol. Jan 2007;80(949):e27-9. [Medline].

  32. Bosch MM, Boon ME. Fine-needle cytology of an eccrine spiradenoma of the breast: diagnosis made by a holistic approach. Diagn Cytopathol. 1992;8(4):366-8. [Medline].

  33. Jitsukawa K, Sueki H, Sato S, Anzai T. Eccrine spiradenoma. An electron microscopic study. Am J Dermatopathol. Apr 1987;9(2):99-108. [Medline].

  34. Meybehm M, Fischer HP. Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol. Apr 1997;19(2):154-61. [Medline].

  35. Ishihara M, Mehregan DR, Hashimoto K, et al. Staining of eccrine and apocrine neoplasms and metastatic adenocarcinoma with IKH-4, a monoclonal antibody specific for the eccrine gland. J Cutan Pathol. Feb 1998;25(2):100-5. [Medline].

  36. Yasui S, Ando I, Kukita A, Hino H, Ohara K. DF3 (CA15-3) antibody as a marker of cutaneous adnexal tumors. Acta Derm Venereol. Mar 1994;74(2):98-100. [Medline].

  37. Saboorian MH, Kenny M, Ashfaq R, Albores-Saavedra J. Carcinosarcoma arising in eccrine spiradenoma of the breast. Report of a case and review of the literature. Arch Pathol Lab Med. May 1996;120(5):501-4. [Medline].

  38. Kurokawa I, Nishimura K, Tarumi C, et al. Eccrine spiradenoma: co-expression of cytokeratin and smooth muscle actin suggesting differentiation toward myoepithelial cells. J Eur Acad Dermatol Venereol. Jan 2007;21(1):121-3. [Medline].

  39. Ko JY, Lee CW, Moon SH, Song KW, Park CK. Giant vascular eccrine spiradenoma: report of a case with immunohistochemical study. J Korean Med Sci. Feb 2006;21(1):172-6. [Medline].

  40. Ohtsuki Y, Ohtsuka H, Kurabayashi A, et al. Immunohistochemical and electron microscopic studies of Langerhans cells in a case of multiple eccrine spiradenomas. Med Mol Morphol. Dec 2007;40(4):221-5. [Medline].

  41. Sridhar KS, Benedetto P, Otrakji CL, Charyulu KK. Response of eccrine adenocarcinoma to tamoxifen. Cancer. Jul 15 1989;64(2):366-70. [Medline].

  42. Mirza I, Kloss R, Sieber SC. Malignant eccrine spiradenoma. Arch Pathol Lab Med. May 2002;126(5):591-4. [Medline].

  43. Martins C, Bartolo E. Brooke-Spiegler syndrome: treatment of cylindromas with CO2 laser. Dermatol Surg. Sep 2000;26(9):877-80; discussion 881. [Medline].

  44. Hantash BM, Chan JL, Egbert BM, Gladstone HB. De novo malignant eccrine spiradenoma: a case report and review of the literature. Dermatol Surg. Sep 2006;32(9):1189-98. [Medline].

  45. Lara JF, Nadeem MA, Asaadi M. Malignant mixed tumor ex eccrine spiradenoma: an unusual pattern of malignant dedifferentiation. Ann Diagn Pathol. Jun 2001;5(3):155-61. [Medline].

  46. Liapakis IE, Korkolis DP, Koutsoumbi A, Fida A, Kokkalis G, Vassilopoulos PP. Malignant hidradenoma: a report of two cases and review of the literature. Anticancer Res. May-Jun 2006;26(3B):2217-20. [Medline].

  47. Michal M, Lamovec J, Mukensnabl P, Pizinger K. Spiradenocylindromas of the skin: tumors with morphological features of spiradenoma and cylindroma in the same lesion: report of 12 cases. Pathol Int. May 1999;49(5):419-25. [Medline].

  48. Rajan N, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associatedwith reduced DKK2 expression. J Pathol. Jul 2011;3:309-21. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.